Want to see SPRB full AI Analyst Report?
Total Valuation
Spruce Biosciences has a market cap or net worth of $148.24M. The enterprise value is $42.66.
Market Cap$148.24M
Enterprise Value$42.66
Share Statistics
Spruce Biosciences has 2,874,013 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,874,013
Owned by Insiders1.04%
Owned by Institutions37.19%
Financial Efficiency
Spruce Biosciences’s return on equity (ROE) is -0.92 and return on invested capital (ROIC) is -84.42%.
Return on Equity (ROE)-0.92
Return on Assets (ROA)-0.73
Return on Invested Capital (ROIC)-84.42%
Return on Capital Employed (ROCE)-0.85
Revenue Per Employee0.00
Profits Per Employee-1.77M
Employee Count22
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Spruce Biosciences is ―. Spruce Biosciences’s PEG ratio is 0.04.
PE Ratio―
PS Ratio0.00
PB Ratio1.57
Price to Fair Value1.57
Price to FCF-2.00
Price to Operating Cash Flow-2.94
PEG Ratio0.04
Income Statement
In the last 12 months, Spruce Biosciences had revenue of 0.00 and earned -38.97M in profits. Earnings per share was -50.83.
Revenue0.00
Gross Profit0.00
Operating Income-36.51M
Pretax Income-38.97M
Net Income-38.97M
EBITDA-38.85M
Earnings Per Share (EPS)-50.83
Cash Flow
In the last 12 months, operating cash flow was -42.62M and capital expenditures -145.00K, giving a free cash flow of -42.77M billion.
Operating Cash Flow-42.62M
Free Cash Flow-42.77M
Free Cash Flow per Share-14.88
Dividends & Yields
Spruce Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-10.28
52-Week Price Change548.81%
50-Day Moving Average48.61
200-Day Moving Average66.30
Relative Strength Index (RSI)61.54
Average Volume (3m)80.64K
Important Dates
Spruce Biosciences upcoming earnings date is Nov 16, 2026, After Close (Confirmed).
Last Earnings DateAug 12, 2026
Next Earnings DateNov 16, 2026
Ex-Dividend Date―
Financial Position
Spruce Biosciences as a current ratio of 5.17, with Debt / Equity ratio of 9.16%
Current Ratio5.17
Quick Ratio5.17
Debt to Market Cap0.00
Net Debt to EBITDA1.24
Interest Coverage Ratio-405.70
Taxes
In the past 12 months, Spruce Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Spruce Biosciences EV to EBITDA ratio is -0.48, with an EV/FCF ratio of -0.56.
EV to Sales0.00
EV to EBITDA-0.48
EV to Free Cash Flow-0.56
EV to Operating Cash Flow-0.56
Balance Sheet
Spruce Biosciences has $96.30M in cash and marketable securities with $7.67M in debt, giving a net cash position of $88.62M billion.
Cash & Marketable Securities$96.30M
Total Debt$7.67M
Net Cash$88.62M
Net Cash Per Share$30.84
Tangible Book Value Per Share$55.46
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Spruce Biosciences is $153.17, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$153.17
Price Target Upside255.54% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast-100.00%
EPS Growth Forecast52.43%